Infectious Disease Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

This study tested a new injectable option called cabotegravir to prevent HIV in adults at risk of infection. Nearly 1,000 participants in Kenya and Uganda took part, and the results are now available. This option could offer a more flexible and effective way to prevent HIV compared to current methods, potentially making it easier for people to protect themselves from HIV.

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

This Phase 3 trial tested an oral antiviral pill named S-217622 designed to stop people exposed to COVID-19 from developing symptoms. The study included over 3,700 participants from multiple countries and has completed with results ready. If proven effective, this treatment could become a new way to reduce the risk of getting sick after being around someone with COVID-19.

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

This Phase 3 trial looked at ensitrelvir, an antiviral pill, for hospitalized COVID-19 patients to help them recover faster and reduce the severity of illness. Over 600 patients from several countries took part, and the results are now available. This treatment could serve as an additional option alongside current care to improve outcomes for people seriously ill with COVID-19.

Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge

This ongoing Phase 3 trial tests a new monoclonal antibody treatment aimed at preventing malaria in children recovering from severe malaria or severe anaemia. Conducted in Kenya, it follows children for a year after leaving the hospital. If successful, this could provide longer-lasting protection and reduce repeat hospital visits and deaths in these vulnerable children.

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

This Phase 3 trial is currently recruiting adults and adolescents at high risk of severe COVID-19 to test an antiviral drug called secutrelvir. The goal is to see if it lowers hospitalizations and serious complications. The study is happening in multiple countries including the United States and aims to enroll 2,000 participants, with results expected in the future.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.